<DOC>
	<DOCNO>NCT01439282</DOCNO>
	<brief_summary>This Phase 2 , multicenter , single-arm , feasibility study evaluate eribulin combination capecitabine adjuvant chemotherapy regimen approximately 65 subject early-stage ( I-II ) , human epidermal growth factor receptor 2 ( HER2 ) - normal , estrogen receptor ( ER ) -positive breast cancer .</brief_summary>
	<brief_title>Eribulin Combination With Capecitabine Adjuvant Treatment Estrogen Receptor-Positive Early Stage Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>1 . Male subject age great equal 18 year female subject must postmenopausal ( least 12 month consecutive amenorrheic bilateral oophorectomy , hysterectomy ovary intact , female must age 55 old postmenopausal folliclestimulating hormone [ FSH ] level ) . 2 . Subject candidate chemotherapy adjuvant setting . Adjuvant therapy must begin within 84 day final surgical procedure breast cancer . 3 . Histologically confirm Stage I II invasive breast cancer . Subjects may one synchronous primary breast tumor . 4 . Receptor Status : HER2normal determine negative fluorescence situ hybridization ( FISH ) result 0 1+ immunohistochemistry ( IHC ) stain result ERpositive , nodenegative ERpositive Grade 1 2 nodepositive breast cancer 5 . ECOG performance status 0 1 6 . Adequate renal function evidence serum creatinine less equal 1.5 mg/dL calculate creatinine clearance great equal 50 mL/min per Cockcroft Gault formula 7 . Adequate bone marrow function evidence ANC great equal 1.5 x 10^9/L , hemoglobin great equal 10.0 g/dL , platelet count great equal 100 x 10^9/L 8 . Adequate liver function evidence bilirubin less equal 1.5 time upper limit normal ( ULN ) alkaline phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 x ULN 9 . Male subject must successful vasectomy ( confirm azoospermia ) , female partner must childbearing potential , male subject must agree use female partner use highly effective method contraception ( e.g. , total abstinence , intrauterine device , doublebarrier method [ condom plus diaphragm spermicide ] throughout entire study period 30 day study drug discontinuation.. 10 . Voluntary agreement provide write informed consent willingness ability comply aspects protocol 1 . Stage III IV invasive breast cancer 2 . Prior chemotherapy , radiation therapy , immunotherapy biotherapy current breast cancer 3 . Nonmalignant systemic disease ( cardiovascular , renal , hepatic , etc ) would preclude study therapy drug 4 . Subjects concurrently active second malignancy adequately treat nonmelanoma skin cancer situ cervical cancer 5 . Subjects preexist neuropathy great Grade 2 6 . Subjects know positive human immunodeficiency virus ( HIV ) status 7 . Females childbearing potential . Females consider childbearing potential unless postmenopausal ( least 12 month consecutive amenorrheic bilateral oophorectomy , hysterectomy ovary intact , female must age 55 old postmenopausal FSH level ) . 8 . Subjects current gastrointestinal disease condition result inability take absorb oral medication 9 . Subjects know allergy hypersensitivity eribulin mesylate excipients , fluoropyrimidine therapy ( without document dihydropyrimidine dehydrogenase [ DPD ] deficiency ) 10 . A clinically significant electrocardiogram ( ECG ) abnormality , include mark baseline prolongation QT/QTc interval ( time start Q wave end T wave/QT interval correct heart rate ) ( e.g. , repeated demonstration QTc interval great 500 m ) 11 . Any medical condition , opinion investigator , would preclude participation clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Estrogen Receptor-Positive Early Stage Breast Cancer</keyword>
</DOC>